The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review by Cramer, J A et al.
The signiﬁcance of compliance and persistence in the
treatment of diabetes, hypertension and dyslipidaemia:
a review
J. A. Cramer,
1 A ´. Benedict,
2 N. Muszbek,
2 A. Keskinaslan,
3 Z. M. Khan
4
Introduction
Hypertension, dyslipidaemia and diabetes are well-
known risk factors for cardiovascular disease (CVD),
which is a leading cause of death and disability
worldwide (1–5). Large-scale clinical trials have
shown that pharmacological treatment can reduce
the morbidity and mortality associated with CVD
and that long-term or lifelong treatment is often
indicated (6–9).
According to the World Health Organization,
non-compliance with long-term medication for con-
ditions such as hypertension, dyslipidaemia and dia-
betes is a common problem that leads to
compromised health beneﬁts and serious economic
consequences in terms of wasted time, money and
uncured disease (10). In addition, a recent editorial
referred to the overwhelming evidence for a decrease
in morbidity and mortality with the use of antihy-
pertensive therapy, and concluded that the greatest
potential for improving control of hypertension lies
in improving patient compliance (11).
Compliance with medication has become a topic
of much research, and various interventions have
been proposed to improve patient compliance. How-
ever, it has proved difﬁcult to compare studies of
compliance because of a lack of standard terminol-
ogy and methodology. Two recent Cochrane reviews
1Yale University School of
Medicine, West Haven, CT, USA
2United BioSource Corporation,
Budapest, Hungary and London,
UK
3Novartis Pharma AG, Basel,
Switzerland
4Novartis Pharmaceuticals
Corporation, East Hanover, NJ,
USA
Correspondence to:
Joyce A. Cramer,
Yale University School of
Medicine, 950 Campbell Ave,
(Room 7-127, G7E), West
Haven, CT 06516-2770, USA
Tel.: + 1 203 937 3894
Fax: + 1 203 937 3468
Email: joyce.cramer@yale.edu
Disclosures
The data in this paper were
presented in part at the 16th
European Meeting on
Hypertension, 12–15 June
2006, Madrid, Spain and ISPOR
9th Annual European Congress,
28–31 October 2006,
Copenhagen, Denmark.
Development of this manuscript
was sponsored by Novartis
Pharma AG. Joyce Cramer does
not have a direct or indirect
ﬁnancial interest in Novartis
Pharma AG, nor has she
received an honorarium to
author this manuscript. A ´gnes
Benedict and Noe ´mi Muszbek
are employees of United
BioSource. As a research
organisation, United BioSource
conducted the original literature
review upon which this article
is based. United BioSource has
undertaken similar projects for
other pharmaceutical
companies. Abdulkadir
Keskinaslan and Zeba M. Khan
are directly employed by
Novartis Pharma AG and
Novartis Pharmaceuticals
Corporation respectively.
Editorial support was provided
by Rx Communications Limited.
OnlineOpen:This article is available free online at www.blackwell-synergy.com             
SUMMARY
Objectives: To review studies of patient compliance/persistence with cardiovascu-
lar or antidiabetic medication published since the year 2000; to compare the meth-
ods used to measure compliance/persistence across studies; to compare reported
compliance/persistence rates across therapeutic classes and to assess whether com-
pliance/persistence correlates with clinical outcomes. Methods: English language
papers published between January 2000 and November 2005 investigating patient
compliance/persistence with cardiovascular or antidiabetic medication were identi-
ﬁed through searches of the MEDLINE and EMBASE databases. Deﬁnitions and
measurements of compliance/persistence were compared across therapeutic areas
using contingency tables. Results: Of the 139 studies analysed, 32% focused on
hypertension, 27% on diabetes and 13% on dyslipidaemia. The remainder covered
coronary heart disease and cardiovascular disease (CVD) in general. The most fre-
quently reported measure of compliance was the 12-month medication possession
ratio (MPR). The overall mean MPR was 72%, and the MPR did not differ signiﬁ-
cantly between treatment classes (range: 67–76%). The average proportion of
patients with an MPR of > 80% was 59% overall, 64% for antihypertensives,
58% for oral antidiabetics, 51% for lipid-lowering agents and 69% in studies of
multiple treatments, again with no signiﬁcant difference between treatment clas-
ses. The average 12-month persistence rate was 63% and was similar across ther-
apeutic classes. Good compliance had a positive effect on outcome in 73% of the
studies examining clinical outcomes. Conclusions: Non-compliance with cardiovas-
cular and antidiabetic medication is a signiﬁcant problem, with around 30% of
days ‘on therapy’ not covered by medication and only 59% of patients taking
medication for more than 80% of their days ‘on therapy’ in a year. Good compli-
ance has a positive effect on clinical outcome, suggesting that the management of
CVD may be improved by improving patient compliance.
Review Criteria
Studies evaluating adherence, persistence and/or
compliance with cardiovascular or antidiabetic
medication were identiﬁed through searches of the
MEDLINE and EMBASE databases. A manual search
of reference lists from retrieved papers was also
performed. Prespeciﬁed parameters from relevant
papers were recorded and analysed numerically.
Message for the Clinic
A literature review of 139 studies reporting
compliance data showed that non-compliance with
cardiovascular and antidiabetic medication is a
signiﬁcant problem. Only 63% of patients continue
with their medication for a year and patients only
take their medication for 72% of the time, yet in
73% of studies good compliance had a positive
effect on clinical outcomes. Encouraging patients to
comply with their treatment regimens could do
much to improve the clinical management of
cardiovascular disease.
doi: 10.1111/j.1742-1241.2007.01630.x
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lipid-lowering and antihypertensive treatments found
‘substantial heterogeneity’ in the measures of compli-
ance used and therefore did not attempt to combine
speciﬁc studies (12,13).
A literature review of research into patient compli-
ance with antihypertensive, lipid-lowering or oral
antidiabetic medications was therefore performed to
aid current understanding of the medical signiﬁcance
of patient compliance in the treatment of CVD. The
aims of the study were to review original research
papers measuring compliance and/or persistence with
antihypertensives (AHTs), lipid-lowering therapies
(LLTs) and oral antidiabetics (OADs) published
between 2000 and 2005; to compare the methodol-
ogy used within the studies to measure compliance/
persistence; to compare the reported compliance/per-
sistence rates at the study level across the three treat-
ment areas and to assess whether compliance/
persistence correlates with clinical outcomes.
Methods
Searches
Searches for relevant research reports were conducted
using the MEDLINE and EMBASE databases. The
search terms used were: cardiovascular, hypertens*,
hyperlipid*, dyslipid*, blood pressure, diabet*, adher-
ence, persistence and compliance. A manual search
of the reference lists from retrieved papers was also
performed to identify further relevant studies.
Selection criteria
Studies were deemed relevant if they were English
language, human, original research studies published
between January 2000 and November 2005; if they
involved patients with CVD or diabetes; if they
examined compliance and/or persistence with phar-
maceutical interventions (even if the primary objec-
tive was not to measure compliance); and if they
provided a numeric measure of compliance or persis-
tence with an adequate description of the methodol-
ogy used. Posters were included only if available.
Trials of clinical efﬁcacy were not included unless
they speciﬁcally investigated compliance. As the
objective of any clinical trial is to maintain compli-
ance at the highest possible level and as it is neces-
sary to adhere to a protocol, such studies were not
considered to be relevant to this assessment of com-
pliance because they would be biased and skewed
towards high compliance. The search was restricted
to the 5-year period 2000–2005 to capture recent
studies.
Studies were excluded from analysis if the study
design and methods for calculating compliance/
persistence were not appropriately described; if
no numeric value for compliance/persistence was
reported; if they examined non-compliance with
antiplatelets, aspirin, digoxin, insulin, non-pharma-
ceutical therapies or treatment guidelines; and if they
were reviews of earlier research papers, letters to the
editor, commentaries or conference abstracts.
Data extraction
Parameters extracted from the studies included study
design, country of study, number of patients, mean
age of patients (weighted averages for studies with
multiple treatment arms), mean study length (med-
ian if mean not available or time-frame of data col-
lection if mean and median not available), deﬁnition
of compliance or persistence, unit of measure of
compliance or persistence and type of funding. No
limits were set on the number of patients or the
study length. Studies supported by industry (such as
pharmaceutical companies, managed care organisa-
tions and consultancies) were identiﬁed, but unre-
stricted grants from pharmaceutical companies were
considered to be non-industry funded.
Patients were classiﬁed as having hypertension,
diabetes, dyslipidaemia, CVD or coronary heart dis-
ease (CHD). Myocardial infarction (MI) and heart
failure were included under CHD, while stroke/tran-
sient ischaemic attack and other unspeciﬁed cardio-
vascular conditions were classiﬁed under CVD.
Treatments were divided into AHTs, OADs and
LLTs. Studies examining two or three therapeutic
classes were categorised as ‘multiple treatment’.
Compliance deﬁnitions, measurements
and data sources
Two common measures of compliance are adherence
(sometimes used as a synonym for compliance) and
persistence. Adherence refers to the proportion of
pills taken within a speciﬁc time interval and persis-
tence refers to the continuing use (in time) of the
prescribed therapy (14). To aid future research into
compliance, the Medication Compliance and Persis-
tence Special Interest Group (MCP SIG) of the Inter-
national Society for Pharmacoeconomics and
Outcomes Research has proposed standard interna-
tional deﬁnitions of medication compliance (adher-
ence) and persistence (Figure 1) (15).
A commonly used measure of compliance is the
mean medication possession ratio (MPR). This is
usually deﬁned as the number of days of treatment
dispensed divided by the number of days between
prescription reﬁlls (excluding the last prescription)
(16). For example, a patient who receives daily treat-
ment and is prescribed 90 days of medication but
does not reﬁll the prescription for a further 10 days
Re-use of this article is
permitted in accordance with
the Creative Commons Deed,
Attribution 2.5, which does not
permit commercial exploitation.
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used measure of compliance is the percentage of
patients with an MPR of more than 80% over a certain
period of time, although the rationale for this cut-off
point is often not justiﬁed and it is not necessary to
use categorical rather than continuous data. A com-
monly used measure of persistence is the percentage of
patients who are persistent with treatment at 1 year.
For this review, deﬁnitions of compliance and per-
sistence, and their method of measurement, were
recorded. Data on the MPR or the percentage of
patients with an MPR of more than 80% at 1 year
were extracted and analysed numerically. The per-
centage of patients persisting with treatment after
1 year was also analysed. All measures were classiﬁed
as either continuous (able to take on any value, such
as MPR) or discrete (limited to speciﬁc values). One
compliance rate was calculated for each study. In
studies with multiple treatment arms, population-
weighted averages were used.
The sources of prospectively collected compliance
data in the studies were also identiﬁed and classiﬁed
as either electronic monitoring using standard pill
bottles ﬁtted with microprocessors to record the time
and frequency of bottle openings (Medication Event
Monitoring System, MEMS); pill counts, comprising
the number of pills left in a returned container; or
questionnaires. Retrospectively collected data using
pharmacy claims (de-identiﬁed data from adminis-
trative databases) were also noted. In studies with
multiple data sources, the most sophisticated data
source was recorded using the order MEMS > pill
count > pharmacy claims data > questionnaire.
The relationship between compliance and patient
outcome was investigated by recording clinical
parameters (such as systolic or diastolic blood pres-
sure, glycated haemoglobin levels and total blood
cholesterol levels) and events (such as hospitalisa-
tions and emergency room visits). Cases were then
classiﬁed according to the relationship between good
compliance and persistence, and the change in out-
come. For example, a positive relationship was taken
as a positive change in outcome with good compli-
ance, while a neutral relationship was taken as no
change in outcome with good compliance.
Statistical analysis
Results were presented in contingency tables. Associ-
ations between categorical variables were assessed
using the chi-squared test and Fisher’s exact test.
Patient numbers and age, and study length, were
compared using the t-test and Mann–Whitney test.
The level of signiﬁcance was taken as p < 0.05.
Results
Study characteristics
A total of 151 papers were identiﬁed from the litera-
ture search. A list of these papers is provided in the
Appendix. From these papers, 139 studies which sat-
isﬁed the inclusion criteria were identiﬁed, and were
included in the analysis. Of the 139 studies, approxi-
mately one-third (31.6%) focused on hypertension,
27.3% on diabetes and 13.0% on dyslipidaemia. The
remainder involved patients with CHD (17.3%) or
CVD (10.8%). The majority of studies investigated
one therapeutic class, and most were studies of AHTs
(38.1%), followed by OADs (25.2%), LLTs (mostly
statins; 23.0%) and multiple treatments (13.7%).
Compliance deﬁnitions, measurement and data
sources
The deﬁnitions and measures of compliance varied
considerably between studies. Deﬁnitions were often
not compatible with the standard MCP SIG deﬁni-
tions (Figure 1). Eighty-eight studies (63%) exam-
ined compliance only, 18 (13%) persistence only and
33 (24%) examined both compliance and persistence.
The studies measuring both compliance and persis-
tence were mostly retrospective in design, and were
more likely to focus on LLTs (41%) than AHTs
(17%), OADs (23%) or multiple treatments (10%).
Medication Compliance (Synonym: Adherence) is the extent to which a 
patient acts in accordance with the prescribed dosing regimen. The unit of 
measure is administered doses per defined period of time, reported as the 
proportion of prescribed doses taken in the prescribed time interval.
Medication Persistence is the accumulation of time from initiation to 
discontinuation of therapy, measured by time metric.
Figure 1 Deﬁnitions of medication compliance and persistence proposed by the Issues and Methods Deﬁnitions Working
Group of the Medication Compliance and Persistence Special Interest Group (15)
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measure for compliance and 57 of these applied at
least one cut-off value. The most common cut-off
value applied to the MPR was 80% (43 studies).
Analysis of the sources of compliance data showed
that the largest number of studies used pharmacy
claims data, followed by questionnaires, MEMS,
‘other’ sources and pill counts (Figure 2).
Compliance
The most frequently reported measure of compli-
ance was the 12-month MPR. The overall mean
MPR was 72% [standard deviation (SD) 0.18],
showing that only 72% of days ‘on therapy’
were actually covered by medication. The mean
12-month MPR did not differ signiﬁcantly between
therapeutic classes (Table 1). The overall proportion
of patients with an MPR of > 80% was 59% (SD
0.19), showing that only 59% of patients had medi-
cation for more than 80% of their days ‘on therapy’
in the year. The proportion of patients with an
MPR above 80% at 12 months was highest for
AHTs (64%), followed by OADs (58%) and LLTs
(51%), but the differences between therapeutic
classes were not signiﬁcant.
Persistence
Many different measures of persistence were used
over many different time frames. The 12-month per-
sistence rate varied from 35.1% to 92.0% for the 22
estimates, with an average of 63.3% (SD 0.18). Per-
sistence rates were similar for the different therapeu-
tic classes (61.8% for AHTs, 62.3% for OADs and
65.6% for LLTs). There was a statistically signiﬁcant
trend towards decreased persistence with time
(p < 0.001; Figure 3). The average persistence rate
across the European studies was 61.7% over a mean
observation period of 17 months. This compared
with an average persistence rate of 51.1% in the US
studies over a mean observation period of
21 months.
Clinical outcomes
Fifty of the 139 studies (36%) reported outcomes.
These comprised clinical parameters (e.g. systolic or
diastolic blood pressure, blood glycated haemoglobin
or cholesterol levels) or events (e.g. hospitalisations
or emergency room visits). Therapeutic class did not
appear to affect the relationship between compliance
and outcome, whereas study design did; prospective
studies were more likely than retrospective studies to
show a relationship (p ¼ 0.0001; Table 2).Studies
using MEMS as a source of data were also signiﬁ-
cantly more likely to link compliance and outcome
than studies using pharmacy claims (p ¼ 0.004;
Table 2).
The relationship between compliance and outcome
was investigated in 41 of the 50 studies reporting
outcomes. In 30 studies (73%), the effect of good
compliance on outcome was positive, and a positive
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Figure 2 Source of compliance data over time
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(7%). Only eight studies (20%) found good compli-
ance to have a neutral or implied neutral effect on
outcome.
Study trends
An analysis of study trends according to the year
of publication showed that the proportion of retro-
spective studies increased signiﬁcantly between 2000
and 2005 (p ¼ 0.002 for trend; Table 3). The use
of continuous measures of compliance also
increased signiﬁcantly, while the use of discrete
measures decreased (p ¼ 0.009 for trend). Discrete
measures are used most often in cross-sectional
surveys and questionnaires, suggesting that use of
such data sources became less common over the
5-year period. The average number of patients in
each study, the mean patient age, the average
study length, the distribution of studies across
therapeutic class, the country of study and the
source of funding did not change between 2000
and 2005.
A comparison of retrospective and prospective
studies showed that prospective studies were more
likely to be European based, to involve fewer patients
(mean 893 vs. 15,123 for retrospective studies;
p ¼ 0.001) and to be shorter in length (mean
12.5 months vs. 23.2 months for retrospective stud-
ies; p ¼ 0.001) than retrospective studies. In addi-
tion, prospective studies were more likely to be
funded by industry (54% funded by industry vs. 22%
of retrospective studies; p ¼ 0.00008).
Table 1 Compliance results by therapeutic class, study design and data source
Measure
Therapeutic class (%) Study design (%) Data source (%)
AHTs
(n ¼ 53)
OADs
(n ¼ 35)
LLTs
(n ¼ 32)
Total*
(n ¼ 139)
Prospective
(n ¼ 65)
Retrospective
(n ¼ 54)
MEMS
(n ¼ 21)
Pharmacy
claims
(n ¼ 73)
Average 12-month MPR 67 (12) 76 (10) 74 (8) 72 (34) 79 (5) 71 (29) 75 (4) 71 (29)
Proportion of patients with
MPR > 80% at 12 months
64 (7) 58 (7) 51 (9) 59 (28) 67 (6) 57 (22) 65 (3) 57 (23)
Number of studies (n) are shown in parentheses. *Includes studies with multiple treatment arms. AHTs, antihypertensives; LLTs, lipid-
lowering therapies; MEMS, medication event monitoring system; MPR, medication possession ratio; OADs, oral antidiabetics.
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Figure 3 Persistence rates from the different studies, showing a signiﬁcant trend (p < 0.001) towards decreased persistence
with time
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Patient numbers, the mean age of patients and the
source of funding did not differ signiﬁcantly between
therapeutic classes. A higher proportion of LLT studies
were retrospective (72%) compared with other thera-
peutic classes (40% for AHTs, 57% for OADs, 50% for
multiple treatments), and there was a signiﬁcant asso-
ciation between study design and therapeutic class
(p ¼ 0.042). LLT studies also showed the longest
study duration (mean 30.1 months vs. 15.3 months
for AHTs, 18.0 months for OADs, 10.7 months for
multiple treatments). The mean study duration was
signiﬁcantly different between therapeutic classes
(p ¼ 0.001). Studies of multiple groups of treatments
were shorter in duration than studies of a single group
of medications (mean study duration 10.7 vs.
20.3 months respectively; p ¼ 0.001).
Discussion
The results of this study conﬁrm the view that com-
pliance and persistence with cardiovascular medica-
tion is poor, regardless of the method used for data
collection (10,11). In terms of compliance, patients
ﬁlled 72% of prescriptions in the ﬁrst year of treat-
ment. Thus, almost 30% of days ‘on therapy’ were
not actually covered by medication. Furthermore,
only 59% of patients had medication for more than
80% of their days ‘on therapy’ in the year. The
results of one study with a follow-up of more than
2 years showed that compliance decreases at ﬁrst but
then reaches a plateau (17).
Persistence also decreased with time, but with wide
variability. The reasons for the variability in persis-
tence rates are unclear. The 10% point difference
between European and North-American persistence
rates may have been due to differences in the average
follow-up time between the different studies. How-
ever, other factors are clearly involved. In a study
comparing compliance with statin therapy in Italy
and Denmark, 91% of patients remained persistent
after 2 years in Denmark, but only 48% remained
persistent at this time in Italy (18). No single expla-
nation for the difference emerged from the study,
although differences in prescribing practices between
the two countries could have played a role.
This systematic review conﬁrmed previous ﬁndings
that the deﬁnitions and measures of compliance vary
considerably between studies (12,13). However, there
were some encouraging signs of a move towards
using standard methodology, especially in retrospec-
tive analyses of pharmacy claims, in which MPR was
Table 2 Percentage of studies reporting outcomes by therapeutic class, study design and data source
Outcome reported
Therapeutic class (%) Study design** (%) Data source*** (%)
AHTs
(n ¼ 53)
OADs
(n ¼ 35)
LLTs
(n ¼ 32)
Total*
(n ¼ 139)
Prospective
(n ¼ 65)
Retrospective
(n ¼ 54)
MEMS
(n ¼ 21)
Pharmacy
claims (n ¼ 73)
Clinical parameter 30.8 28.6 34.4 28.1 40.0 29.6 52.4 17.8
Event 7.7 5.7 9.4 7.9 12.3 5.6 14.3 4.1
None 61.5 65.7 56.3 64.0 47.7 64.8 33.3 78.1
Results are presented as percentages of the number of studies in each group. *Includes studies with multiple treatment arms. **p ¼ 0.0001 for test of indepen-
dence of factors. ***p ¼ 0.004 for test of independence of factors. AHTs, antihypertensives; LLTs, lipid-lowering therapies; MEMS, medication event monitoring
system; OADs, oral antidiabetics.
Table 3 Study characteristics according to the year of publication
Publication Study design (%) Compliance measure (%)
year N Prospective Retrospective Continuous Discrete
2000 13 69 31 54 46
2001 18 78 22 50 50
2002 29 24 76 79 21
2003 28 57 43 82 18
2004 31 35 65 77 23
2005 20 40 60 90 10
Total 139 47 53 75 25
p-value for trend 0.002 0.009
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move towards the use of a standard measure for
compliance, it should become easier to compare esti-
mates of compliance, enabling the inﬂuence of
patient or regimen characteristics on compliance to
be determined.
Many of the studies analysed in this review used
the deﬁnition of MPR proposed by Steiner and Proc-
hazka (16). It has been argued that it is more infor-
mative to report the percentage of patients above a
certain threshold of MPR rather than mean MPR
(19). However, the authors of this review believe that
graphic presentation of the whole distribution as a
histogram along with mean, SD or quintiles is prefer-
able. Presenting compliance and persistence over
time graphically is also very informative, as charted
in 25 of the studies included in this review [see for
example Sturkenboom et al. (20)].
The most important reason for investigating these
issues is that poor compliance and lack of persistence
with medications for hypertension, hyperlipidaemia
and diabetes potentially lead to suboptimal health
outcomes. Around one-third of studies in this review
investigated the effect of compliance on outcomes,
and the majority (73%) showed that compliance has
a positive inﬂuence on outcome. Only one instance
of a marginally negative effect of compliance on out-
come (raised systolic blood pressure) was identiﬁed
(21) and only a few studies found compliance to
have a neutral effect on outcome (22–26). In addi-
tion, two of the studies reviewed (27,28) found mor-
tality rates to be lower in more compliant patients.
A number of recent studies have shown that
patients who are compliant with therapy are likely to
have better outcomes. In a meta-analysis, which
included cardiovascular studies, a consistent associa-
tion between good adherence to drug therapy and
reduced mortality was found (29). Similarly,
increased compliance and persistence with long-term
cardiovascular therapy have been shown to reduce
the risk of adverse cardiovascular outcomes; compli-
ant patients (MPR   80%) showing a reduced pre-
dicted relative risk of 4.6% for men and 16.4% for
women (11). Another study showed that patients
who were highly compliant with antihypertensive
therapy were 45% more likely to achieve blood pres-
sure control than those with medium or low compli-
ance (odds ratio 1.45, p ¼ 0.026) (30).
In another study investigating the relationship
between persistence (deﬁned as < 60 days gap
between reﬁlls) with antihypertensive therapy and
the risk of MI/stroke, multivariate analysis showed
that persistent users were at signiﬁcantly lower risk
of MI/stroke than non-persistent patients (relative
risk 0.88, 95% conﬁdence interval: 0.82–0.94) (31).
Better compliance with antihypertensive therapy has
also been shown to reduce the risk of hospitalisation
(32), while better compliance with antidiabetic medi-
cation has been shown to reduce emergency room
visits by 26% over a 2- to 3-year period (33).
Over the 5-year period of the present study, a
trend towards more retrospective studies using data
collected from pharmacy claims databases was seen.
This was not surprising given that such studies take
less time and money than prospective studies and
potentially provide larger numbers of patients.
One limitation of the present review is that one
person selected the studies and extracted the data.
Thus, relevant studies may have been missed or
incorrectly categorised. Another limitation is that
although study characteristics and compliance mea-
sures were examined at the study level, differences
between treatment arms within studies (e.g. different
classes of AHTs, different doses) were not investi-
gated. In studies with multiple treatment arms, popu-
lation-weighted averages were used to calculate
compliance. Meta-analysis was beyond the scope of
this review. Because of the number of papers
included in the review, study characteristics were
presented only in tabular form. In addition, only
means and SDs of compliance measures were calcu-
lated, without multivariate analysis. Finally, semi-
transparency of deﬁnitions in some papers made it
difﬁcult to determine whether methods, and conse-
quently compliance measures, were truly comparable.
Prospective real-world studies that use standard
deﬁnitions and measures of compliance, and focus
on objective outcomes, such as mortality, are needed
to further our understanding of the issue of compli-
ance. Large retrospective studies that analyse existing
databases, identify appropriate stratiﬁcation sub-
groups and use modelling exercises would also be
useful.
Conclusions
In this systematic review, poor compliance and per-
sistence with cardiovascular and antidiabetic medica-
tion proved to be a signiﬁcant problem, with almost
30% of days ‘on therapy’ not actually covered by
medication and only 59% of patients having medica-
tion for more than 80% of their days ‘on therapy’ in
the year. The deﬁnitions and measures of compli-
ance/persistence used varied widely between studies
making comparisons difﬁcult. However, there were
signs of a move towards the use of standard termi-
nology and methodology. The most frequent mea-
sure of compliance was the 12-month MPR, which
did not differ between therapeutic classes. Similarly,
12-month persistence rates did not differ between
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towards a decrease over time. The majority of studies
investigating the relationship between compliance
and outcome found that compliance had a positive
effect on outcome, suggesting that the management
of CVD may be improved by improving patient
compliance.
Further research into the problem of poor compli-
ance with cardiovascular and antidiabetic medication
is warranted to increase the number of published
studies in this area and to increase awareness of the
problem. By increasing awareness, it may be possible
to improve patient compliance. The availability of
different targeted interventions, including behaviour-
al training and electronic devices designed speciﬁcally
to improve patient compliance, may also contribute
to improved compliance and persistence, and hence
to improved clinical outcomes.
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